{
    "clinical_study": {
        "@rank": "124326", 
        "arm_group": {
            "arm_group_label": "Lipotecan, injection for chemotherapy", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "INVESTIGATIONAL PRODUCT:\n\n      TLC388 (Lipotecan*) *Lipotecan is a drug product of TLC388 HCl.\n\n      PHASE OF DEVELOPMENT:\n\n      Phase II\n\n      No. OF PATIENTS:\n\n      Approximately 40 (Stage I: 15 evaluable patients, Stage II: 25 evaluable patients)\n\n      STUDY OBJECTIVES:\n\n      Primary\n\n      \u2022 To evaluate non-progression disease (non-PD) rate at the end of cycle 6\n\n      Secondary\n\n        -  To evaluate progression free survival (PFS)\n\n        -  To evaluate overall survival (OS)\n\n        -  To evaluate the duration of non-PD\n\n        -  To evaluate objective response rate (ORR; where ORR= CR+PR) and duration\n\n        -  To evaluate the safety profile of TLC388\n\n        -  To evaluate change in health-related quality of life (HRQOL) at the end of cycle 6\n\n      STUDY DESIGN:\n\n      This is a Phase II, open-label, single-arm, multi-centre study to evaluate TLC388\n      monotherapy in patients with locally advanced and/or metastatic renal cell carcinoma (RCC)."
        }, 
        "brief_title": "A Phase II Study to Evaluate the Efficacy and Safety of TLC388 in Advanced/Metastatic RCC Patients", 
        "condition": "Advanced/Metastasis Renal Cell Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Renal Cell", 
                "Neoplasm Metastasis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients defined by age \u2265 18 years\n\n          -  Histologically confirmed Renal cell carcinoma (RCC)\n\n          -  Locally advanced or metastatic RCC. Locally advanced RCC: defined as a stage . .\n             T3/T4 disease, not amenable to curative surgery or radiation therapy, with\n             involvement of renal vein/vena cava/peripelvic and perirenal fat/adrenal gland, or\n             invasion beyond Gerota's fascia (Moch et al., 2009). Metastatic RCC: equivalent to\n             Stage IV RCC, according to American Joint Committee on Cancer (AJCC) staging\n\n          -  Eastern Collaborative Oncology Group (ECOG) Performance Status of \u2264 2. An ECOG of \u2264 1\n             for the patient with failure of >= 2 prior target therapies is acceptable\n\n          -  Documented RCC disease with measurable or non-measurable lesion on imaging by RECIST\n             v1.1 (Response Evaluation Criteria in Solid Tumors) criteria\n\n          -  Documented treatment failure of at least 1 prior target therapy (sorafenib, sunitinib\n             pazopanib or other VEGF TKI, bevacizumab, temsirolimus, everolimus or other mTOR\n             inhibitor) for advanced or metastatic RCC. If treatment-na\u00efve, . patients with poor\n             prognosis features according to Memorial Sloan-Kettering Cancer Centre (MSKCC) risk\n             criteria are acceptable\n\n          -  Any acute or chronic adverse effects of prior therapy have resolved to <Grade 2 as\n             determined by CTCAE v4.0 criteria\n\n          -  Laboratory values at screening:\n\n               -  Absolute neutrophil count \u2265 1,500 /mm3;\n\n               -  Platelets \u2265 100,000 /mm3;\n\n               -  Hemoglobin \u2265 9.0 g/dL;\n\n               -  Total bilirubin \u2264 1.5 times the upper limit of normal;\n\n               -  AST (SGOT) \u2264 2.5 times the upper limit of normal;\n\n               -  ALT (SGPT) \u2264 2.5 times the upper limit of normal;\n\n               -  Serum creatinine \u2264 2 times the upper limit of normal;\n\n        Exclusion Criteria:\n\n          -  Pregnancy or lactation. Women of childbearing potential must have a negative serum\n             pregnancy test within 7 days prior to enrolment. Male and female patients of\n             childbearing potential must agree to use appropriate birth control (barrier methods\n             with spermicides, oral or parenteral contraceptives and/or intrauterine devices)\n             during the entire duration of the study, or the patient must be surgically sterile\n             (with documentation in the patient's medical records)\n\n          -  Receipt of any chemotherapy for RCC\n\n          -  Had cardiac angioplasty or stenting event, myocardial infarction or unstable angina\n             within 3 months of study entry\n\n          -  Persistent QTc >450 ms for males, or >470 ms for females, according to Fridericia's\n             correction\n\n          -  Patients with Grade 3 or greater hyponatremia at screening\n\n          -  History of Class III or IV congestive heart failure according to New York Heart\n             Association (NYHA) classification\n\n          -  History of another malignancy, except for non-basal-cell carcinoma of skin or\n             carcinoma-in-situ of the uterine cervix, and not disease free \u22655 years\n\n          -  History or presence of central nervous system (CNS) metastasis or leptomeningeal\n             tumors as documented by CT or MRI scan, analysis of cerebrospinal fluid or\n             neurological exam\n\n          -  History of human immunodeficiency virus infection\n\n          -  Presence of active, uncontrolled infection\n\n          -  Radiotherapy received within 4 weeks prior to baseline\n\n          -  Use of any investigational agents within 4 weeks of baseline\n\n          -  Major surgery within 4 weeks prior to baseline\n\n          -  Receipt of radiotherapy to >25 % of bone marrow\n\n          -  Concomitant treatment with, or anticipated use of, pharmaceutical or herbal agents\n             which are potent inhibitors or inducers of cytochrome P450 enzymes (Appendix D1),\n             unless approved by the Sponsor\n\n          -  Uncontrolled intercurrent illness that would jeopardize patient safety, or interfere\n             with the objectives of the protocol, or limit patient compliance with study\n             requirements, as determined by the Investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01831973", 
            "org_study_id": "TLC388.3"
        }, 
        "intervention": {
            "arm_group_label": "Lipotecan, injection for chemotherapy", 
            "intervention_name": "Lipotecan", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 10, 2013", 
        "location": [
            {
                "contact": {
                    "email": "chuang8270@adm.cgmh.org.tw", 
                    "last_name": "Yao-Chi Chuang, MD", 
                    "phone": "886-7-7317123 #", 
                    "phone_ext": "8094"
                }, 
                "facility": {
                    "address": {
                        "city": "Kaohsiung", 
                        "country": "Taiwan", 
                        "zip": "833"
                    }, 
                    "name": "Chang Gung Memorial Hospital. Kaohsiung Branch"
                }, 
                "investigator": {
                    "last_name": "Yao-Chi Chuang, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "ycou@vghtc.gov.tw", 
                    "last_name": "Yen-Chuan Ou, MD", 
                    "phone": "886-4-23592525", 
                    "phone_ext": "5121"
                }, 
                "facility": {
                    "address": {
                        "city": "Taichung", 
                        "country": "Taiwan", 
                        "zip": "407"
                    }, 
                    "name": "Taichung Veterans General Hospital"
                }, 
                "investigator": {
                    "last_name": "Yen-Chuan Ou, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "urology8395@yahoo.com.tw", 
                    "last_name": "Chao-Hsiang Chang, MD", 
                    "phone": "886-4-22052121", 
                    "phone_ext": "4323"
                }, 
                "facility": {
                    "address": {
                        "city": "Taichung", 
                        "country": "Taiwan", 
                        "zip": "404"
                    }, 
                    "name": "China Medical University Hospital"
                }, 
                "investigator": {
                    "last_name": "Chao-Hsiang Chang, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "cyhuang0909@ntu.edu.tw", 
                    "last_name": "Chao-Yuan Huang, MD", 
                    "phone": "886-2-23123456", 
                    "phone_ext": "65238"
                }, 
                "facility": {
                    "address": {
                        "city": "Taipei", 
                        "country": "Taiwan", 
                        "zip": "10002"
                    }, 
                    "name": "National Taiwan University Hospital"
                }, 
                "investigator": {
                    "last_name": "Chao-Yuan Huang, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "Wen1902@hotmail.com", 
                    "last_name": "Wen-Cheng Chang, MD", 
                    "phone": "886-3-3281200", 
                    "phone_ext": "8475"
                }, 
                "facility": {
                    "address": {
                        "city": "Taoyuan", 
                        "country": "Taiwan", 
                        "zip": "333"
                    }, 
                    "name": "Chang Gung Memorial Hospital: LinKou Branch"
                }, 
                "investigator": {
                    "last_name": "Wen-Cheng Chang, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-Label, Single-Arm, Multi-center Phase II Study to Evaluate the Efficacy and Safety of TLC388 in Patients With Advanced/Metastatic Renal Cell Carcinoma", 
        "overall_contact": {
            "email": "zoe@tlcbio.com", 
            "last_name": "Zoe Hsiao, BS", 
            "phone": "+886-26557377", 
            "phone_ext": "206"
        }, 
        "overall_official": {
            "affiliation": "Taiwan Liposome Company", 
            "last_name": "Min-Hsiung Kao, MS", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Taiwan: Department of Health", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Evaluate non-progression disease (non-PD) rate at the end of cycle 6", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01831973"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Evaluate progression free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Evaluate overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Evaluate the duration of non-PD", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Evaluate objective response rate (ORR; where ORR= CR+PR) and duration", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Evaluate the safety profile of TLC388", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Evaluate change in health-related quality of life (HRQOL) at the end of cycle 6", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Taiwan Liposome Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Taiwan Liposome Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}